Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C.
作者信息
Padkin A, Rowan K, Black N
机构信息
Health Services Research Unit, Department of Public Health and Policy, London School of Hygiene, London, UK.
出版信息
BMJ. 2001 Oct 20;323(7318):923-6. doi: 10.1136/bmj.323.7318.923.
Abstract
摘要
相似文献
1
Using high quality clinical databases to complement the results of randomised controlled trials: the case of recombinant human activated protein C.利用高质量临床数据库补充随机对照试验结果：重组人活化蛋白C的案例
BMJ. 2001 Oct 20;323(7318):923-6. doi: 10.1136/bmj.323.7318.923.
2
Treatment of sepsis with activated protein C.用活化蛋白C治疗脓毒症。
BMJ. 2001 Oct 20;323(7318):881-2. doi: 10.1136/bmj.323.7318.881.
3
[Activated protein C, coagulation, inflammation and treatment of severe sepsis].
Ned Tijdschr Geneeskd. 2001 Jun 16;145(24):1179.
4
[Activated protein C, coagulation, inflammation and treatment of severe sepsis].
Ned Tijdschr Geneeskd. 2001 Jun 16;145(24):1178-9.
5
Activated protein C: beyond 28 days.活化蛋白C：超过28天。
Crit Care Med. 2004 Nov;32(11):2348-9. doi: 10.1097/01.ccm.0000146137.32072.f7.
6
Still puzzled by additional data from the PROWESS study.
Crit Care Med. 2005 Sep;33(9):2146; author reply 2146-7. doi: 10.1097/01.ccm.0000179027.22630.78.
7
Severe sepsis, coagulation, and fibrinolysis: dead end or one way?严重脓毒症、凝血和纤溶：死胡同还是单行道？
Crit Care Med. 2012 Sep;40(9):2704-8. doi: 10.1097/CCM.0b013e318258ff30.
8
Substantiating the concerns about recombinant human activated protein C use in sepsis.证实对重组人活化蛋白C用于脓毒症治疗的担忧。
Crit Care Med. 2004 Dec;32(12):2542-3. doi: 10.1097/01.ccm.0000148090.94378.6a.
9
[Activated protein C in sepsis].[脓毒症中的活化蛋白C]
Tidsskr Nor Laegeforen. 2004 Mar 18;124(6):766.
10
[Recombinant human activated protein C for sepsis: When should it be indicated?].
Rev Assoc Med Bras (1992). 2003 Jul-Sep;49(3):232-3. doi: 10.1590/s0104-42302003000300013. Epub 2003 Nov 5.
引用本文的文献
1
Attrition in a Multidisciplinary Pediatric Weight Management Clinic.一家多学科儿科体重管理诊所的患者流失情况。
Child Obes. 2011 Jun 20;7(3):185-193. doi: 10.1089/chi.2011.0010.
2
Comparison of Charlson comorbidity index with SAPS and APACHE scores for prediction of mortality following intensive care.比较 Charlson 合并症指数与 SAPS 和 APACHE 评分对 ICU 后死亡率的预测
Clin Epidemiol. 2011;3:203-11. doi: 10.2147/CLEP.S20247. Epub 2011 Jun 17.
3
Appointment attendance in a pediatric weight management clinic.儿科体重管理诊所的预约就诊情况。
Clin Pediatr (Phila). 2012 Sep;51(9):888-91. doi: 10.1177/0009922811410876. Epub 2011 May 27.
4
Biomedical informatics and outcomes research: enabling knowledge-driven health care.生物医学信息学与结果研究：推动知识驱动型医疗保健
Circulation. 2009 Dec 8;120(23):2393-9. doi: 10.1161/CIRCULATIONAHA.108.795526.
5
Databases as policy instruments. About extending networks as evidence-based policy.作为政策工具的数据库。关于扩展网络作为循证政策。
BMC Health Serv Res. 2007 Dec 7;7:200. doi: 10.1186/1472-6963-7-200.
6
Secular trends in severe renal failure associated with the use of new antimicrobial agents in critically ill surgical patients.危重症外科患者使用新型抗菌药物相关的严重肾衰竭的长期趋势。
Eur J Clin Microbiol Infect Dis. 2007 Jun;26(6):395-402. doi: 10.1007/s10096-007-0305-5.
7
Coping with methodological dilemmas; about establishing the effectiveness of interventions in routine medical practice.应对方法学困境；关于确立常规医疗实践中干预措施的有效性
BMC Health Serv Res. 2006 Dec 13;6:160. doi: 10.1186/1472-6963-6-160.
8
[Trends in surgical intensive care. Experience in one centre over 12 years].[外科重症监护的发展趋势。一个中心12年的经验]
Chirurg. 2006 Aug;77(8):700-8. doi: 10.1007/s00104-006-1204-5.
9
Changes in glaucoma treatment and achieved IOP after introduction of new glaucoma medication.新型青光眼药物引入后青光眼治疗的变化及眼压控制情况
Graefes Arch Clin Exp Ophthalmol. 2006 Oct;244(10):1267-72. doi: 10.1007/s00417-005-0241-y. Epub 2006 Mar 17.
本文引用的文献
1
Evidence based policy: proceed with care.循证政策：谨慎行事。
BMJ. 2001 Aug 4;323(7307):275-9. doi: 10.1136/bmj.323.7307.275.
2
Efficacy and safety of recombinant human activated protein C for severe sepsis.重组人活化蛋白C治疗严重脓毒症的疗效与安全性
N Engl J Med. 2001 Mar 8;344(10):699-709. doi: 10.1056/NEJM200103083441001.
3
Consequences of discharges from intensive care at night.夜间重症监护病房出院的后果。
Lancet. 2000 Apr 1;355(9210):1138-42. doi: 10.1016/S0140-6736(00)02062-6.
4
Subgroup analysis and other (mis)uses of baseline data in clinical trials.临床试验中基线数据的亚组分析及其他（不当）用途。
Lancet. 2000 Mar 25;355(9209):1064-9. doi: 10.1016/S0140-6736(00)02039-0.
5
Threats to applicability of randomised trials: exclusions and selective participation.随机试验适用性面临的威胁：排除标准与选择性参与
J Health Serv Res Policy. 1999 Apr;4(2):112-21. doi: 10.1177/135581969900400210.
6
Unlicensed and off label drug use in paediatric wards: prospective study.儿科病房中未获许可及超说明书用药情况：前瞻性研究
BMJ. 1998 Jan 31;316(7128):343-5. doi: 10.1136/bmj.316.7128.343.
7
What are pragmatic trials?什么是实用性试验？
BMJ. 1998 Jan 24;316(7127):285. doi: 10.1136/bmj.316.7127.285.
8
Why we need observational studies to evaluate the effectiveness of health care.为什么我们需要观察性研究来评估医疗保健的有效性。
BMJ. 1996 May 11;312(7040):1215-8. doi: 10.1136/bmj.312.7040.1215.
9
Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic Therapy Trialists' (FTT) Collaborative Group.疑似急性心肌梗死的溶栓治疗指征：超过1000例患者的所有随机试验早期死亡率和主要发病率结果的协作综述。纤维蛋白溶解疗法试验者（FTT）协作组
Lancet. 1994 Feb 5;343(8893):311-22.
10
Assessing the quality of randomized controlled trials: an annotated bibliography of scales and checklists.评估随机对照试验的质量：量表与清单注释 bibliography
Control Clin Trials. 1995 Feb;16(1):62-73. doi: 10.1016/0197-2456(94)00031-w.
Zotero 插件